http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018213713-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c6a86831170132d420b8f108ce9eafef |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-30 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444 |
| filingDate | 2018-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cdce8d050773e21e1665ad8a9983a87c |
| publicationDate | 2018-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2018213713-A1 |
| titleOfInvention | Compositions and methods for the treatment of addiction, psychiatric disorders, and neurodegenerative disease |
| abstract | The present invention is based, in part, on our discovery that certain types of therapeutic agents may be used in combination to treat a variety of neuropsychiatric and related disorders, including addiction (e.g., to a substance or activity) as well as to alleviate some symptoms associated with other diseases or conditions. Regardless of precise formulation, the compositions of the invention may include one ingredient that targets the hypothalamo-pituitary- adrenal (HPA) axis and at least one active ingredient that targets the prefrontal cortex. Either or both of these types of agents may be combined with an agent that inhibits activity in the sympathetic nervous system. Thus, the compositions or combination pharmacotherapies can also include an agent that inhibits a beta-adrenergic receptor or that otherwise acts as an antihypertensive or anxiolytic agent. The present invention also includes treatment of cocaine-use disorder with a combination of metyrapone and oxazepam, while avoiding serious adverse events and reducing the likelihood of relapse by blunting Cortisol increase associated with stress and cocaine use. |
| priorityDate | 2017-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 596.